Share Name Share Symbol Market Type Share ISIN Share Description
Silence Ther. LSE:SLN London Ordinary Share GB00B9GTXM62 ORD 5P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00p +0.00% 166.50p 165.00p 168.00p - - - 0 06:31:56
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.8 -10.4 -12.1 - 116.54

Silence Therapeutics (SLN) Latest News (1)

More Silence Therapeutics News
Silence Therapeutics Takeover Rumours

Silence Therapeutics (SLN) Share Charts

1 Year Silence Therapeutics Chart

1 Year Silence Therapeutics Chart

1 Month Silence Therapeutics Chart

1 Month Silence Therapeutics Chart

Intraday Silence Therapeutics Chart

Intraday Silence Therapeutics Chart

Silence Therapeutics (SLN) Discussions and Chat

Silence Therapeutics Forums and Chat

Date Time Title Posts
23/8/201707:14Silence Therapeutics (the old SR Pharma)47,343
06/10/201609:04Gower Productions Presents ....."PREDICTA BID"52
29/5/201310:32Silence Therapeutics - news and views1,412
15/2/201308:57SLN - I see no ships, but I do see 10p looming, ahoy!368

Add a New Thread

Silence Therapeutics (SLN) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2017-08-22 15:50:48160.8711,45818,432.80O
2017-08-22 15:15:25166.84548914.30O
2017-08-22 15:02:26165.002,6744,412.10AT
2017-08-22 15:02:08165.00100165.00AT
2017-08-22 15:02:07165.00500825.00AT
View all Silence Therapeutics trades in real-time

Silence Therapeutics (SLN) Top Chat Posts

Silence Therapeutics Daily Update: Silence Ther. is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker SLN. The last closing price for Silence Therapeutics was 166.50p.
Silence Ther. has a 4 week average price of 119.75p and a 12 week average price of 93.75p.
The 1 year high share price is 166.50p while the 1 year low share price is currently 72.75p.
There are currently 69,991,624 shares in issue and the average daily traded volume is 56,286 shares. The market capitalisation of Silence Ther. is £116,536,053.96.
1gw: I am surprised we haven't had a rush of short-term players to the bulletin boards, given the share price chart. All the better for the future, perhaps, if the share price has done what it has done without much input from the bulletin boards or twitter.
1gw: ARWR is up around 20% this afternoon - not enough to take me into profit on my holding, but makes the loss look a little less severe. They beat on revenue and earnings, thanks (I think) to the Amgen up-front payments, and also announced an analyst R&D day for September to explain what they're doing. They described the Amgen partnership as working well and said in response to a question that they were interested in similar partnerships with other companies and are optimistic that they can enter into additional strategic partnerships. No obvious follow-through to the SLN share price yet, but perhaps ARWR's spike (on heavy volume) will draw some attention to other companies in the sector.
1gw: Well let's hope the ARWR call this evening will be a material event! It's a good point on cash vs market cap/EV. According to the preliminaries, at 31st December they held: £39.0m cash & equivalents £4.4m available-for-sale financial assets (mainly ARWR shares) So £43.4m between the two categories. With about 70m shares in issue that's equivalent to about 62p in cash/equivalents and financial assets. Since year-end they've converted some of the cash into more ARWR shares and they will have burnt through some more cash in running the business. But even so, with a share price in the 70's that's not a lot for the ongoing business, IP, R&D and pipeline. Which is hard to reconcile with Ali's upbeat comments on valuation of RNA therapeutics, for example, in the RNS on the ARWR purchase: "We believe that the recent technological advancements in RNA therapeutics have been underestimated and undervalued. We are confident that the recent market approval of medicines in our field are the beginning of the emergence of an important new class of therapeutics. " So I've bought a third tranche this afternoon - registering as a buy this time.
1gw: Thanks calumross. Thank goodness for the summary slide at the end! Rather alarming share price behaviour today, ahead of ARWR results.
partner: New game to play , watch the arrowhead share price !!. we appear to be in profit already (subject to currency fluctuations).
callumross: "Success in business can often hinge on opportunities taken (or indeed spurned). Yes, you require a good product, or stellar technology and, of course, decent management. But sometimes company-defining moments come down to happenstance and then having the lead-lined stomach to take the plunge. Silence Therapeutics (LON:SLN) has done just that – taken the plunge - with its US$9.6mln acquisition of an 8.4% stake in Arrowhead Pharmaceuticals (NASDAQ:ARWR). Whether it proves to be a pivotal investment only time will tell. At the very least it looks like a well-timed transaction. Less than six months ago, when Arrowhead was valued at just shy of US$730mln, buying a shareholding of this scale was inconceivable (not mention too expensive). Then fate and poor luck intervened (for Arrowhead at least). In November it cancelled three clinical programmes for drugs designed to tackle liver disease, which caused the stock to tumble to a low of US$1.20 from that August high-point of US$8.22. Silence will have been looking on with interest – not least because the two companies are in the same area of research; they are pioneers in RNA interference (RNAi). This is the cellular process of silencing unwanted or harmful genes. The two companies also use similar delivery mechanisms – GalNAc liver technology - so there ought to be areas where the pair can collaborate. The investment starts the ball rolling in this regard – it is a conversation opener. “Any number of scenarios are possible from mergers, takeovers, cross-collaboration, licensing and at default level maybe nothing,” said Silence’s chief executive Ali Mortazavi. “We have taken a worst case that we are left we with a passive investment.” The UK firm is not alone in having taken a view on Arrowhead and backed that hunch with cold hard cash. The giant Amgen handed over an initial US$56.5mln in September to buy into RNAi therapies being developed to tackle cardiovascular disease as part of a deal worth US$617mln in staged payments. It is worth noting the equity investment at US$7.16 a share provided support for a US$500mln valuation of Arrowhead. Amgen’s interest lies with the firm’s GalNAc technology, which is unaffected by November’s decision. In fact, analysts say the platform has significant untapped potential. If the market has spotted the value still inherent in Arrowhead it has been slow to react. Silence has been far quicker to cotton on. “We are in the field and so are much more knowledgeable about what’s happening,” said Mortazavi. Technologies such as Silence’s and Arrowhead’s are undergoing clinical and preclinical assessment yet the market has assigned both discount valuations. Yet the CRISPR gene editing technology, still very much in its infancy, is receiving billions of dollars of investment cash from big pharma, while listed companies are valued between $500mln and $1bn. This is frustrating for those operating in RNAi, though it is also helped create the “extraordinary circumstances” that allowed Silence to make its move. “A lot of different stars aligned at the same time and Arrowhead fell right back into our zone,” said Mortazavi. “There wasn’t [just] one single reason we did this. At its best this could be a very, very important moment in RNA interference and the ability to actually be able to capture something. “These opportunities don’t come around very often and they may be defining moments.” One should remember Silence is first and foremost a drug development company, not an investment vehicle. “We are going down the development path ourselves. You must not forget this,” said Mortazavi. Indeed, the company continues to use its own IP and know-how to progress its liver-targeted preclinical pipeline. In addition, it is expecting pivotal clinical results from its out-licensed phase III and phase II programmes in mid-2018. The share price, up 4%, suggests the market likes the Arrowhead deal. Equally, investors don’t seem to be getting too carried away. And neither is boss Mortazavi: “We are in a place where any number of things can happen, including nothing.”
callumross: Milestone payments announced yesterday are for Quark entering Phase 3 and are IN ADDITION to the 15% which is still only a possibility depending on the outcome of phase 3 trials (the primary endpoint in the quark Phase 2 trial of 30% was achieved in a very specific subset of patients amounting to 50% of the trial participants). Surprised we didn't see a strong bounce in the share price on the announcement yesterday.
pwilk47490: Share Price slump gaining momentum! :-(
benson384: Waterloo........SLN won courtcase in Europe re-patent challenged by Alnylam (?). They thought ir worth challenging along with 3 other co's and lost. The amount of money they have and their market Cap circa $8-10bn why not just buy SLN.....? For years I have heard that SLN's tecnology/delivery is way ahead of Yanks so why not just now buy it........? Victor Kiam style !!!! Waterloo, I think you ben about a long time so your memory may pick up points I am raising and agree.........who cares all we want is a share price that now reflects the progress that has been made and the future £5 now looks cool £10 in £18 months mayeven look cheap......who knows.? No knowledge other than published and kept eye on this outfit for many years, I amy be wrong but patience is tittering on cliff of rich/reward versus sh.t...... Very open to critiscm by all, re my thoughts.
the_doctor: 'No faith in the bod here' It isnt the bod's fault There has been little they can do The issue has been that a) SLN was ramped up by IR's lot + posters on here, but failed to deliver deals b) RNAi in general has moved out of favour pending further data = SLN share price was hammered down and funds have been raised at worsening levels It is now really a case of - seeing what tech deals they can get (they've just done a small one) - keeping existing deals going (AZ renewed and Dainippon progressing) - hoping that external clinical products continue and give milestones (out of their hands) - moving Atu027 forwards and driving a deal there (scheduled for 2012) - leveraging Atu027 to push for more tech deals (as above) - keeping other tech platforms moving forward They've been doing all that. Not really a whole lot more the bod can do.
Silence Therapeutics share price data is direct from the London Stock Exchange
Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:41 V: D:20170823 06:18:59